Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07787130

Effect of Immune X on Common Cold Incidence in Healthy Adults

The goal of this clinical trial is to learn if Immune X can help prevent common cold events in healthy adults who have a history of upper respiratory tract infections. The main questions it aims to answer are:

* Does Immune X reduce the proportion of participants who experience at least one clinically confirmed common cold event during the study period? * Does Immune X affect the number, duration, and severity of common cold events?

Researchers will compare Immune X to a placebo (a look-alike capsule containing inactive ingredients) to see if Immune X helps prevent common cold events.

Participants will:

* Take Immune X or placebo daily for 16 weeks during the winter season. * Attend study visits at the beginning and end of the study and complete questionnaires and symptom assessments throughout the study. * Record cold symptoms, medications, and other study information using a smartphone application. * Provide blood and stool samples during the study.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men and women aged 18 to 65 years.
  • History of at least two upper respiratory tract infections during the previous winter season.
  • Body mass index between 18 and 30 kg/m².
  • Generally healthy, as determined by the investigator.
  • Women of childbearing potential must have a negative pregnancy test and agree to use an effective method of contraception during the study.
  • Covered by French health insurance.
  • Able and willing to provide written informed consent.

Exclusion criteria

  • Current or recent upper respiratory tract infection or COVID-19 infection within 2 weeks before enrollment.
  • Acute gastrointestinal infection, including gastroenteritis, within 2 weeks before enrollment.
  • Use of non-steroidal anti-inflammatory drugs (NSAIDs) within 2 weeks before enrollment.
  • Use of systemic antibiotics within 3 months before enrollment.
  • Receipt of any vaccination within 6 weeks before enrollment.
  • Surgery requiring general anesthesia within 1 month before enrollment.
  • History of chronic respiratory disease, including asthma or chronic obstructive pulmonary disease.
  • Food allergy or chronic/recurrent allergic upper airway conditions requiring regular medical treatment, including moderate to severe allergic rhinitis, hay fever, or chronic rhinosinusitis.
  • Acute lower respiratory tract infection within 6 months before enrollment or ongoing long COVID.
  • Immunodeficiency (including HIV infection) or autoimmune disease, except stable hypothyroidism.
  • Severe or uncontrolled chronic disease, including cancer, significant liver, pancreatic, biliary, or renal disease, inflammatory bowel disease, or cardiovascular disease requiring intensive medical management.
  • Untreated or inadequately controlled diabetes.
  • History or current diagnosis of periodontitis.
  • Current chemotherapy, immunosuppressive therapy, or chronic treatment with corticosteroids or opioids.
  • Specific diets or major dietary changes within 3 months before enrollment, including high-protein, vegan, low-calorie, or low-FODMAP diets, or participation in a weight-loss program.
  • Current use of dietary supplements that may affect immune or gut microbiota parameters, or discontinuation of such supplements less than 6 weeks before enrollment.
  • Current smoking or e-cigarette use, or smoking cessation within 6 months before enrollment.
  • Current drug or alcohol abuse, or a history of abuse within the previous 12 months.
  • Regular consumption of more than 2 alcoholic drinks per day and unwillingness to maintain stable drinking habits during the study.
  • Unwillingness to refrain from using over-the-counter cold remedies, nasal washes or sprays, antihistamines, corticosteroids, or NSAIDs during the study.
  • More than 8 hours per week of vigorous physical activity or planned major changes in physical activity during the study.
  • Any condition or circumstance that, in the investigator's judgment, may place the participant at unacceptable risk or interfere with study participation or interpretation of study results.
  • Current participation in another clinical trial or being in an exclusion period from a previous clinical trial.
  • Pregnant or breastfeeding.
  • Persons deprived of liberty, under legal protection, or unable to provide informed consent.
  • Individuals who have reached the regulatory compensation limit for participation in clinical research.

Treatment and study plan

Immune X

Dietary Supplement

500 mg Immune X daily as capsules for 16 weeks.

Placebo

Other

Matching placebo capsules daily for 16 weeks.

Primary outcomes

  1. Participants With at Least One Clinically Confirmed Cold Event

    Time frame: Week 2 to Week 16

    Proportion of participants with at least one clinically confirmed cold event.

Secondary outcomes

  1. Number of Clinically Confirmed Cold Events

    Time frame: Week 2 to Week 16

    Mean number of clinically confirmed cold events per participant.

  2. Duration of Clinically Confirmed Cold Events

    Time frame: Week 2 to Week 16

    Duration of clinically confirmed cold events measured in days.

  3. Upper Respiratory Symptoms of Clinically Confirmed Cold Events

    Time frame: Week 2 to Week 16

    Wisconsin Upper Respiratory Symptom Survey (WURSS-24): Zero is equivalent to no symptoms and 7 indicates severe.

  4. Cold Symptoms of Clinically Confirmed Cold Events

    Time frame: Week 2 to Week 16

    Jackson Cold Scale: 0 is equivalent to absent symptoms and 3 indicates severe symptoms

  5. Illness-Specific Quality of Life During Cold Events

    Time frame: Week 2 to Week 16

    Wisconsin Upper Respiratory Symptom Survey (WURSS-24) quality-of-life score: Zero is equivalent to no interference and 7 indicates severe interference.

  6. Time to First Clinically Confirmed Cold Event

    Time frame: Week 2 to Week 16

    Number of days from Day 15 after randomization to the first clinically confirmed cold event.

  7. Fatigue

    Time frame: Baseline, Weeks 4, 8, 12, and 16

    Chalder Fatigue Questionnaire (CFQ-11) total score: 0 is equivalent to less/better than usual and 33 indicates much more/much worse than usual.

  8. Use of Rescue Medication During Cold Events

    Time frame: Week 2 to Week 16

    Number of doses and duration of rescue medication use during cold events.

  9. Number of Cold Events (Clinically Confirmed and Unconfirmed)

    Time frame: Week 2 to Week 16

    Mean number of clinically confirmed and unconfirmed cold events per participant.

  10. Adverse Events

    Time frame: Baseline through Week 16

    Number of participants with adverse events.

Study contacts

Contact information is provided by the study sponsor or research team.

Katja A. Schönenberger, PhD

CONTACT

[email protected]

+41 52 354 01 11

Linda Lopez, PhD

CONTACT

[email protected]

+41 52 354 01 11

Sponsors and collaborators

Lead sponsor

Givaudan France Naturals

Industry

Collaborators

  • CEN Expérimental

Registry information

Official study title

The Effect of Immune X on the Incidence of the Common Cold in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Trial

Acronym: CELFI

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Aug 26, 2026
Registry last updated
Aug 26, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.